BiotechTube
Constantiam Bio

Constantiam Bio

Cambridge, United States· Est.
constantiambio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

Constantiam Biosciences is a private, pre-revenue biotech founded in 2020 and based in Cambridge, USA. It has developed a core technology platform integrating massively multiplexed functional assays with human genetic data and Bayesian machine learning to generate functional evidence for genetic variants. The company's primary focus is on serving the rare disease and oncology markets by providing tools and insights for VUS resolution, target discovery, and clinical trial optimization through its RareScan, Genable, StratiVar, and MAVEvidence platforms.

OncologyRare DiseasesImmunology

Technology Platform

Integrated platform combining Deep Mutational Scanning (DMS) high-throughput functional assays with human genetic data and Bayesian generative machine learning models to interpret genetic variants and predict functional impact.

Funding History

1
Total raised:$10M
Seed$10M

Opportunities

The massive and growing backlog of Variants of Uncertain Significance (VUS) in clinical genetics creates a direct need for high-throughput functional evidence.
The drive towards precision medicine in oncology and rare diseases increases demand for tools that can validate drug targets and stratify patient populations, positioning Constantiam's platforms as potential critical enablers for more efficient drug development.

Risk Factors

Key risks include technical validation of its high-throughput assays in predicting real-world clinical outcomes, competition from established genomic databases and alternative AI-based prediction tools, and the commercial challenge of convincing pharmaceutical and diagnostic partners to adopt a new, unproven platform in a cost-conscious environment.

Competitive Landscape

Constantiam operates in a competitive space that includes large clinical genetics labs (e.g., Quest, Labcorp), public databases (ClinVar, ClinGen), and a growing number of AI/ML-driven genomics startups. Its differentiation hinges on the empirical, experiment-first nature of its DMS data combined with sophisticated Bayesian modeling, as opposed to purely computational prediction methods.

More companies in Digital Health & Biotech SaaS →More companies in United States →